One-Year Outcomes of Early Therapy With Ticagrelor vs Clopidogrel in CYP2C19 Loss-of-Function Carriers With Stroke or TIA Trial.

MLA

Meng, Xia, et al. “One-Year Outcomes of Early Therapy With Ticagrelor vs Clopidogrel in CYP2C19 Loss-of-Function Carriers With Stroke or TIA Trial.” Neurology, vol. 102, no. 3, Feb. 2024, p. e207809. EBSCOhost, https://doi.org/10.1212/WNL.0000000000207809.

APA

Meng, X., Wang, A., Tian, X., Johnston, C., Li, H., Bath, P. M., Xu, Q., Zhang, Y., Xie, X., Jing, J., Lin, J., Wang, Y., Zhao, X., Li, Z., Jiang, Y., Liu, L., & Wang, Y. (2024). One-Year Outcomes of Early Therapy With Ticagrelor vs Clopidogrel in CYP2C19 Loss-of-Function Carriers With Stroke or TIA Trial. Neurology, 102(3), e207809. https://doi.org/10.1212/WNL.0000000000207809

Chicago

Meng, Xia, Anxin Wang, Xue Tian, Claiborne Johnston, Hao Li, Philip M Bath, Qin Xu, et al. 2024. “One-Year Outcomes of Early Therapy With Ticagrelor vs Clopidogrel in CYP2C19 Loss-of-Function Carriers With Stroke or TIA Trial.” Neurology 102 (3): e207809. doi:10.1212/WNL.0000000000207809.